Flex Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.flex-pharma.com
Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS
Phase 1
Withdrawn
- Conditions
- Amyotrophic Lateral SclerosisFasciculation
- Interventions
- Drug: FLX-787-ODT (orally disintigrating tablet)
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Flex Pharma, Inc.
- Registration Number
- NCT03338114
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Flex Pharma, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03334786
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
Phase 2
Terminated
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- Drug: FLX-787-ODT (orally disintegrating tablet)Drug: Placebo ODT
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Flex Pharma, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03254199
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
Phase 2
Terminated
- Conditions
- Motor Neuron Disease
- Interventions
- Drug: Placebo ODTDrug: FLX-787-ODT (orally disintegrating tablet)
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Flex Pharma, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03196375
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Indiana University Neuroscience Center, Indianapolis, Indiana, United States
© Copyright 2025. All Rights Reserved by MedPath